| Pulmonary arterial hypertension
Letairis vs Orenitram
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Letairis vs Orenitram with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrenitram has a higher rate of injection site reactions vs Letairis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orenitram but not Letairis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Letairis
Orenitram
At A Glance
Oral
Daily
Endothelin receptor antagonist
Oral
Two to three times daily
Prostacyclin mimetic
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension Initiate at 5 mg once daily, with or without tadalafil 20 mg once daily; titrate at 4-week intervals as needed and tolerated to Letairis 10 mg or tadalafil 40 mg; do not split, crush, or chew tablets.
Pulmonary arterial hypertension Starting dose 0.125 mg TID or 0.25 mg BID with food; titrate by 0.125 mg TID or 0.25-0.5 mg BID no more frequently than every 3-4 days; maximum daily dose 120 mg.
Contraindications
- Pregnancy (Letairis may cause fetal harm when administered to a pregnant female)
- Idiopathic Pulmonary Fibrosis, including IPF patients with pulmonary hypertension (WHO Group 3)
- Severe hepatic impairment (Child Pugh Class C)
Adverse Reactions
Most common (>3% placebo-adjusted) Peripheral edema, nasal congestion, sinusitis, flushing
Postmarketing Anemia requiring transfusion, heart failure (associated with fluid retention), symptomatic hypotension, hypersensitivity (angioedema, rash), liver aminotransferase elevations (ALT, AST)
Most common (>10%) Headache, diarrhea, nausea, vomiting, jaw pain, flushing
Postmarketing Dizziness, dyspepsia, vomiting, myalgia, arthralgia
Pharmacology
Ambrisentan is a high-affinity, selective ETA receptor antagonist that blocks the vasoconstriction and cell proliferation mediated by endothelin-1 (ET-1) in pulmonary vasculature, where ET-1 concentrations and mRNA are markedly elevated in PAH patients.
Prostacyclin mimetic; treprostinil causes direct vasodilation of pulmonary and systemic arterial vascular beds, inhibits platelet aggregation, and inhibits smooth muscle cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Letairis
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Orenitram
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Letairis
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Orenitram
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Letairis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Orenitram
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Letairis Co-Pay Coupon ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LetairisView full Letairis profile
OrenitramView full Orenitram profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.